Huperzine A for vascular dementia

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Hao, Zilong ^a   Liu, Ming ^a   Liu, Zhiqin ^a   Lv, DongHao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; HUPERZINE A; MEMANTINE; PLACEBO; RIVASTIGMINE; TACRINE;

ABDOMINAL DISTENSION; ANOREXIA; COGNITION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; MULTIINFARCT DEMENTIA; MUSCLE CRAMP; NAUSEA; NEUROPROTECTION; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 55049088230     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007365     Document Type: Review

References (29)

1. Aggarwal 2007 Aggarwal NT, Decarli C. Vascular dementia: emerging trends. Seminars Neurology 2007;27(1):66-77.
2. APA 1980 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd Edition. Washington, DC: APA, 1980.
3. APA 1987 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd Edition. Washington, DC: APA, 1987.
4. APA 1994 American Psychiatric Association. Diagnostic criteria from DSM-4. Washington, DC: APA, 1994.
5. Craig 2004 Craig D, Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD004744.pub2]
6. Craig 2006 Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004746.pub2]
7. Demaerschalk 2007 Demaerschalk BM, Wingerchuk DM. Treatment of vascular dementia and vascular cognitive impairment. The Neurologist 2007;13:37-41.
8. Erkinjuntti 2000 Erkinjuntti T, et al.Research criteria for subcortical vascular dementia in clinical trials. Journal of Neural Transmission 2000;59:23-30.
9. Erkinjuntti 2004 Erkinjuntti T, et al.Treatment of vascular dementia - evidence from clinical trials with cholinesterase inhibitors. Journal of the Neurological Sciences 2004;226:63-6.
10. Farlow 2006 Farlow MR. Use of antidementia agents in vascular dementia: beyond Alzheimer's disease. Mayo Clinic Proceedings 2006;81(10):1350-8.
11. Grossman 2006 Grossman H, et al.Dementia: a brief review. The Mount Sinai Journal of Medicine 2006;73:985-92.
12. Gustavo 2005 Gustavo C, Roman. Vascular dementia prevention: A risk factor analysis. Cerebrovascular Diseases 2005;20(Suppl 2):91-100.
13. Hachinski 1975 Hachinski VC, et al.Cerebral blood flow in dementia. Archives of Neurology 1975;32:632-7.
14. Han 2006 Han Yan, et al.Review on clinical application of Huperzine A in China. New Drugs Clin Rem 2006;25(9):682-8.
15. ICD 1989 Anonymous. The International classification of diseases. 9th Edition. Washington, DC: US Department of Health and Human Services, 1989.
16. Karirajan 2007 Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. LancetNeurology 2007;6:782-92.
17. Knopman 2002 Knopman DS, et al.Incidence of vascular dementia in Rochester, Minn, 1985-1989. Archives of Neurology 2002;59:1605-10.
18. Li 2001 Li HN, et al.Huperzine A improve the cognitive function for patients with vascular dementia: report of the 30 cases. Modern Rehabilitation 2001;5:59.
19. Little 2008 Little JJ, et al.An update on huperzine A as a treatment for Alzheimer's disease. Expert Opinion on Investigational Drugs 2008;17:209-15.
20. Malouf 2004 Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD004395.pub2]
21. McShane 2006 McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD003154.pub5]
22. O'Brien 2003 O'Brien JT, et al.Vascular cognitive impairment. Lancet Neuroloy 2003;2:89-98.
23. O'Brien 2006 O'Brien JT. Vascular cognitive impairment. The American Journal of Geriatric Psychiatry 2006;14:724-33.
24. Roman 2004 Roman GC. Facts, myths, and controversies in vascular dementia. Journal of Neurological Sciences 2004;226(1-2):49-52.
25. Wang 2004 Wang RP, et al.Huperzine A impact on ability of life of patients with vascular dementia: 36 cases of six months follow-up. Chinese Journal of Clinical Rehabilitation 2004;8:3892.
26. Wang 2006 Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacologica Sinica 2006;27(1):1-26.
27. WHO 1992 World Health Organization. The 10th revision of the International Classification of Disease and relative health problems (ICD-10).Geneva: World Health Organization, 1992.
28. Zhang 2006 Zhang HY, Yan H, Tang XC. Neuroprotective effects of huperzine A : new therapeutic targets for neurodegenerative disease. Trends in Pharmacological Sciences 2006;27(12):619-25.
29. Zhong 2004 Zhong ZG, et al.Clinical observation of huperzine A in the treatment of patients with vascular dementia. Journal of Hainan Medical College 2004;10:251-2.